GLAUKOS Corp
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
GKOS$236.19-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
| | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · · · · · · | ||||||||||||||||||||||
| · · · · · · · Additional · · other · · · · · · · · · · · | ||||||||||||||||||||||
| · · Common stock · · paid-in · · comprehensive · · Accumulated · · Treasury stock · · Total | ||||||||||||||||||||||
| · Shares · Amount · capital · income (loss) · deficit · Shares · Amount · equity | ||||||||||||||||||||||
| Balance at December 31, 2021 | | 46,993 | | $47 | | $952,432 | | $15 | | $(365,211) | | (28) | | $(132) | | $587,151 | ||||||
| Common stock issued under stock plans, net | | 789 | | | 1 | | | 6,477 | | | - | | | - | | - | | | - | | | 6,478 |
| Stock-based compensation | | - | | - | | | 38,561 | | | - | | | - | | - | | | - | | | 38,561 | |
| Other comprehensive loss | | - | | - | | | - | | | (2,990) | | | - | | - | | | - | | | (2,990) | |
| Net loss | | - | | - | | | - | | | - | | | (99,195) | | - | | | - | | | (99,195) | |
| Balance at December 31, 2022 | | 47,782 | | $48 | | $997,470 | | $(2,975) | | $(464,406) | | (28) | | $(132) | | $530,005 | ||||||
| Common stock issued under stock plans, net | | 1,366 | | | 1 | | | 15,753 | | | - | | | - | | - | | | - | | | 15,754 |
| Acquired in-process R&D acquired through the issuance of common stock | | - | | | - | | | 3,000 | | | - | | | - | | - | | | - | | | 3,000 |
| Stock-based compensation | | - | | - | | | 43,528 | | | - | | | - | | - | | | - | | | 43,528 | |
| Other comprehensive income | | - | | - | | | - | | | 4,140 | | | - | | - | | | - | | | 4,140 | |
| Net loss | | - | | - | | | - | | | - | | | (134,661) | | - | | | - | | | (134,661) | |
| Balance at December 31, 2023 | | 49,148 | | $49 | | $1,059,751 | | $1,165 | | $(599,067) | | (28) | | $(132) | | $461,766 | ||||||
| Common stock issued under stock plans, net | | 1,972 | | | 2 | | | 40,200 | | | - | | | - | | - | | | - | | | 40,202 |
| Issuance of common stock in exchange for convertible senior notes, net | | 5,297 | | | 5 | | | 300,792 | | | - | | | - | | - | | | - | | | 300,797 |
| Unwinding of capped calls | | - | | | - | | | 53,881 | | | - | | | - | | - | | | - | | | 53,881 |
| Acquired in-process R&D acquired through the issuance of common stock | | 55 | | | - | | | 5,000 | | | - | | | - | | - | | | - | | | 5,000 |
| Stock-based compensation | | - | | | - | | | 50,207 | | | - | | | - | | - | | | - | | | 50,207 |
| Other comprehensive income | | - | | | - | | | - | | | 1,450 | | | - | | - | | | - | | | 1,450 |
| Net loss | | - | | | - | | | - | | | - | | | (146,372) | | - | | | - | | | (146,372) |
| Balance at December 31, 2024 | | 56,472 | | $56 | | $1,509,831 | | $2,615 | | $(745,439) | | (28) | | $(132) | | $766,931 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.